{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T16:07:10Z","timestamp":1781280430400,"version":"3.54.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology Case Reports"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.eucr.2026.103362","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T17:12:51Z","timestamp":1769533971000},"page":"103362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Utility of blue-light cystoscopy and tumor-informed ctDNA for management of recurrent high-risk NMIBC with prostatic urethral involvement: A case report"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-0778","authenticated-orcid":false,"given":"Mahdi Hemmati","family":"Ghavshough","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda Z.","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Sykes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Disha","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saum","family":"Ghodoussipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vignesh T.","family":"Packiam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.eucr.2026.103362_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.3050","article-title":"Management, surveillance patterns, and costs associated with low-grade papillary stage Ta non-muscle-invasive bladder cancer among older adults, 2004-2013","volume":"5","author":"Bree","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.eucr.2026.103362_bib2","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ogc.2021.05.011","article-title":"Urethral masses","volume":"48","author":"Serrell","year":"2021","journal-title":"Obstet Gynecol Clin N Am"},{"issue":"2","key":"10.1016\/j.eucr.2026.103362_bib3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/JU.0000000000000332","article-title":"Re: extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial","volume":"202","author":"Chang","year":"2019","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.eucr.2026.103362_bib4","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","article-title":"Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Gu\u00e9rin","volume":"62","author":"Palou","year":"2012","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.eucr.2026.103362_bib5","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.eucr.2026.103362_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/23523735251324318","article-title":"The role of blue light cystoscopy and additional operative evaluations during first surveillance after induction therapy for high-risk NMIBC","volume":"11","author":"McElree","year":"2025","journal-title":"Bladder Cancer"},{"issue":"4","key":"10.1016\/j.eucr.2026.103362_bib7","doi-asserted-by":"crossref","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN guidelines\u00ae insights: bladder cancer, version 3.2024: featured updates to the NCCN guidelines","volume":"22","author":"Flaig","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"issue":"1","key":"10.1016\/j.eucr.2026.103362_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/1756287213510590","article-title":"Blue-light cystoscopy in the evaluation of non-muscle-invasive bladder cancer","volume":"6","author":"Oude Elferink","year":"2014","journal-title":"Ther Adv Urol"},{"issue":"2","key":"10.1016\/j.eucr.2026.103362_bib9","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000499257","article-title":"Survival outcomes of early versus deferred cystectomy for high-grade non-muscle-invasive bladder cancer: a systematic review","volume":"14","author":"Wan","year":"2020","journal-title":"Curr Urol"},{"issue":"8","key":"10.1016\/j.eucr.2026.103362_bib10","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","article-title":"Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer","volume":"5","author":"Reinert","year":"2019","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.eucr.2026.103362_bib11","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2016.12.016","article-title":"Liquid biopsy analysis of FGFR3 and PIK3CA hotspot mutations for disease surveillance in bladder cancer","volume":"71","author":"Christensen","year":"2017","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.eucr.2026.103362_bib12","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.euo.2025.05.019","article-title":"Real-world experience with a commercial circulating tumor DNA assay in non-muscle-invasive bladder cancer","volume":"8","author":"Wang","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eucr.2026.103362_bib13","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.urology.2023.08.018","article-title":"Cutaneous ureterostomy following radical cystectomy for bladder cancer: a contemporary series","volume":"181","author":"Nabavizadeh","year":"2023","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.eucr.2026.103362_bib14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12894-017-0270-y","article-title":"Transperineal cryotherapy for unresectable muscle invasive bladder cancer: preliminary experience with 7 male patients","volume":"17","author":"Zhang","year":"2017","journal-title":"BMC Urol"},{"key":"10.1016\/j.eucr.2026.103362_bib15","article-title":"Circulating tumor DNA analyses predict disease recurrence in non-muscle-invasive bladder cancer","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"issue":"18","key":"10.1016\/j.eucr.2026.103362_bib16","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"23","key":"10.1016\/j.eucr.2026.103362_bib17","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-23-1860","article-title":"Circulating tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical Follow-up","volume":"29","author":"Lindskrog","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.eucr.2026.103362_bib18","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.eucr.2026.103362_bib19","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41591-022-02199-y","article-title":"High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial","volume":"29","author":"van Dorp","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.eucr.2026.103362_bib20","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1038\/s41598-017-05623-3","article-title":"Association of plasma and urinary mutant DNA with clinical outcomes in muscle invasive bladder cancer","volume":"7","author":"Patel","year":"2017","journal-title":"Sci Rep"}],"container-title":["Urology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214442026000252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214442026000252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:42:37Z","timestamp":1781278957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214442026000252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":20,"alternative-id":["S2214442026000252"],"URL":"https:\/\/doi.org\/10.1016\/j.eucr.2026.103362","relation":{},"ISSN":["2214-4420"],"issn-type":[{"value":"2214-4420","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utility of blue-light cystoscopy and tumor-informed ctDNA for management of recurrent high-risk NMIBC with prostatic urethral involvement: A case report","name":"articletitle","label":"Article Title"},{"value":"Urology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eucr.2026.103362","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103362"}}